Key facts
- ARTBIO’s last known valuation is $190.0M (Dec 2023).
- It has raised $245.0M; the latest was Early Stage VC ($132.0M) in Jul 2025.
- Notable investors include F-Prime Capital, B Capital Group, Alexandria Venture Investments, Qatar Investment Authority, Spur Capital Partners — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for ARTBIO
- ·The full record, as it builds
Funding rounds
No funding rounds for ARTBIO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ARTBIO
Operator of a radiopharmaceutical company intended to offer a new approach to the treatment of cancer. The company specializes in radioligand therapy, which delivers alpha or beta emitters to break down cancer cell DNA and build an ecosystem that maximizes the potential of the therapy, enabling medical practitioners to utilize novel mechanisms in oncology.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 67
- Website
- artbio.com/
- Ownership
- Privately Held (backing)
ARTBIO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ARTBIO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ARTBIO in its N-PORT filings yet. We sweep new filings monthly.